Statins to treat Alzheimer’s disease: An incomplete story

Expert Review of Neurotherapeutics

Volumn 12, Issue 1, 2012, Pages 27-30

  Sabbagh, Marwan n ^a   Sparks, d Larry ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer s disease; atorvastatin; cholesterol; clinical trials; cognitive decline; simvastatin; statins

Indexed keywords

EID: 84858951810     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.171     Document Type: Article

References (25)

1. Sparks DL. Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer’s disease? Ann. NY Acad. Sci. 826, 128 –146 (1997).
2. Dufouil C, Richard F, Fievet N et al. ApoE genotype, cholesterol level, lipid-lowering treatment and dementia. The Three-City Study. Neurology 64, 1531 –1538 (2005).
3. Kivipelto M, Helkala EL, Hallikainen M et al. Elevated systolic blood pressure and high cholesterol levels at midlife are risk factors for late-life dementia. Neurobiol. Aging 21 (1 Suppl.), S174 (2000).
4. Tan ZS, Seshadri S, Beiser A et al. Plasma total cholesterol level as a risk factor for Alzheimer disease. Arch. Intern. Med. 163, 1053 –1057 (2003).
5. Sabbagh MN, Zahiri HR, Ceimo J et al. Is there a characteristic lipid profile in Alzheimer’s disease? J. Alzheimers Dis. 6 (6), 585 –589 (2004).
6. Rockwood K, Kirkland S, Hogan DB et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 59, 223 –227 (2002).
7. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 71, 344 –350 (2008).
8. Etminan M, Gill S, Samii A. The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy 6, 726 –730 (2003).
9. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer’s disease. Neuroepidemiology 23 (1–2), 94 –98 (2004).
10. Li G, Higdon R, Kukull W et al. Statin therapy and risk of dementia in the elderly: a community based prospective cohort study. Neurology 63 (9), 1624 –1628 (2004).
11. Shepherd J. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 360, 1623 –1630 (2002).
12. Group HPSC. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360, 7 –22 (2002).
13. Reiss AB, Wirkowski E. Role of HMG-CoA reductase inhibitors in neurological disorders: progress to date. Drugs 67 (15), 2111 –2120 (2007).
14. Li G, Larson EB, Sonnen JA et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 69, 878 –885 (2007).
15. Arvanitakis Z, Schneider JA, Wilson RS et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 70 (19 Pt 2), 1795 –1802 (2008).
16. Sparks DL, Sabbagh MN, Connor DJ et al. Atorvastatin for the treatment of mild-to-moderate alzheimer’s disease: preliminary results. Arch. Neurol. 62, 753 –757 (2005).
17. Sano M, Bell KL, Galasko D et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 77 (6), 556 –563 (2011).
18. Feldman HH, Doody RS, Kivipelto M et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74 (12), 956 –964 (2010).
19. Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P. Circulating cholesterol levels, apolipoprotein E genotype, and dementia severity influence the benefit of atorvastatin treatment in AD: results from the Alzheimer’s disease Cholesterol Lowering Treatment Trial. Acta Neurol. Scand. 185, S3 –S7 (2006).
20. Park IH, Hwang EM, Hong HS et al. Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. Neurobiol. Aging 24 (5), 637 –643 (2003).
21. Li Y, Iakoubova O, Shiffman D, Devlin JJ, Forrester JS, Superko HR KIF6 polymorphism as a predictor of risk of coronary events and of clinical event reduction by statin therapy. Am. J. Cardiol. 106, 994 –998 (2010).
22. Iakoubova OA, Robertson M, Tong CH et al. KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. Eur. J. Cardiovasc. Prev. Rehabil. 17, 455 –461 (2010).
23. Shiffman D, O’Meara ES, Bare LA et al. Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol. 28, 173 –179 (2008).
24. Medina MW, Gao F, Ruan W, Rotter JI, Krauss RM. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation 118 (4), 355 –362 (2008).
25. Simmons CR, Zou F, Younkin SG, Estus S. Evaluation of the global association between cholesterol-associated polymorphisms and Alzheimer’s disease suggests a role for rs3846662 and HMGCR splicing in disease risk. Mol. Neurodegener. 6, 62 (2011).